[Glybenclamide (HB 419): a new oral antidiabetic agent of the sulfonylurea group].

Suppr

超能文献

作者信息

Mehnert H, Karg E

出版信息

Dtsch Med Wochenschr. 1969 Apr 18;94(16):819-24. doi: 10.1055/s-0028-1111124.

DOI:10.1055/s-0028-1111124

PMID:5776706

Abstract

摘要

相似文献

[Glybenclamide (HB 419): a new oral antidiabetic agent of the sulfonylurea group].

Dtsch Med Wochenschr. 1969 Apr 18;94(16):819-24. doi: 10.1055/s-0028-1111124.

[Clinical studies on the effect of a new oral antidiabetic agent Glybenclamide (HB 419)].

Dtsch Med Wochenschr. 1969 Apr 18;94(16):824-9. doi: 10.1055/s-0028-1111125.

[Oral antidiabetic monotherapy and combination treatment with glybenclamide (HB 419) and biguanides of insulin receiving diabetics of the adult type].

Med Klin. 1970 Jan 16;65(3):109-12.

[Mode of action of blood glucose lowering biguanides: clinical aspects].

Acta Diabetol Lat. 1969 Sep;6 Suppl 1:678-84.

[Oral treatment of diabetes mellitus with the new sulfonylurea tolazamide].

Arzneimittelforschung. 1969 Jul;19(7):1128-30.

[Clinical report of the experience in therapy with oral antidiabetic agent HB 419].

Wien Klin Wochenschr. 1969 Sep 5;81(36):625-8 passim.

[Oral therapy of diabetes].

Presse Med (1893). 1969 Jun 25;77(31):1117-20.

[Long term efficacy and tolerance of antidiabetic treatments. New data].

Nouv Presse Med. 1974 Jun 15;3(24):1551-4.

[Evidence of a reduction of insulin secretion in diabetes with or without obesity. Discussion of the therapeutic use of biguanides].

Ann Endocrinol (Paris). 1969 Nov-Dec;30(6):717-30.

[Oral hypoglycemic agents].

AMB Rev Assoc Med Bras. 1986 Nov-Dec;32(11-12):202-4.

引用本文的文献

Steady-state interactions of glibenclamide with CFTR: evidence for multiple sites in the pore.

J Membr Biol. 2004 May 1;199(1):15-28. doi: 10.1007/s00232-004-0672-0.

[Non-indicated insulin treatment].

Acta Diabetol Lat. 1970 May-Jun;7(3):421-37. doi: 10.1007/BF01556796.

Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride, and glisoxepide. II. Repeated administration in combination with glucose.

Diabetologia. 1971 Dec;7(6):455-60. doi: 10.1007/BF01212062.

Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects.

Diabetologia. 1971 Dec;7(6):449-54. doi: 10.1007/BF01212061.

[Recent findings in the use of 1st and 2nd generation hypoglycemic sulfonamides].

Klin Wochenschr. 1973 Jan 15;51(2):68-77. doi: 10.1007/BF01467758.

[Beta-cytotrophic action of glibenclamide on the pancreas of diabetic patients].

Acta Diabetol Lat. 1972 Mar-Apr;9(2):305-31. doi: 10.1007/BF01564555.

Controlled extension of oral antidiabetic therapy on former insulin dependent diabetics by means of the combined i.v. glibenclamide-glucose-response-test.

Diabetologia. 1972 Feb;8(1):41-7. doi: 10.1007/BF01219985.

Progress in oral therapy of diabetes mellitus with sulphonylureas of the second generation.

Acta Diabetol Lat. 1972 Nov-Dec;9(6):865-99. doi: 10.1007/BF01564590.

Comparative study of the therapeutic effects of glibenclamide or the fixed combination of glibenclamide-phenformin with those of gliclazide or chlorpropamide.

Acta Diabetol Lat. 1990 Jan-Mar;27(1):11-22. doi: 10.1007/BF02624718.

Drug interactions with oral sulphonylurea hypoglycaemic drugs.

Drugs. 1977 Jan;13(1):24-34. doi: 10.2165/00003495-197713010-00003.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验